Hepatocellular carcinoma risk prediction model for the general population: The predictive power of transaminases

Journal of the National Cancer Institute

Volumn 104, Issue 20, 2012, Pages 1599-1611

  Wen, Chi Pang ^a,b   Lin, Jie ^c   Yang, Yi Chen ^a,b   Tsai, Min Kuang ^a,b   Tsao, Chwen Keng ^c,f   Etzel, Carol ^c   Huang, Maosheng ^c   Hsu, Chung Yi ^b   Ye, Yuanqing ^c   Mishra, Lopa ^d   Hawk, Ernest ^e   Wu, Xifeng ^c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Gastroenterology Hepatology and Nutrition   (United States)

^e Division of Cancer Prevention and Population Sciences   (United States)

^f Health Management Institution   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; CALIBRATION; CANCER RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; VALIDATION PROCESS;

ADULT; AGED; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TAIWAN; TUMOR MARKERS, BIOLOGICAL;

EID: 84867728046     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs372     Document Type: Article

References (23)

1. Kuehn BM. Report: too little surveillance, treatment for US patients with hepatitis B and C. Jama. 2010;303(8):713-714.
2. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. www.iom.edu/viralhepatitis. 2010.
3. Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World Journal of Gastroenterology. 2010;16(29):3603-3615.
4. Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 2011;21(1):59-69.
5. U.S. Preventive Services Task Force. Screening for Hepatitis C in Adults. http://www.uspreventiveservicestaskforce.org/uspstf/uspshepc.htm. Accessed July 26, 2012.
6. El-Serag HB. Current concepts hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118-1127.
7. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28(14):2437-2444.
8. Wong VWS, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660-1665.
9. Yuen MF, Tanaka Y, Fong DYT, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50(1):80-88.
10. Ikeda K, Arase Y, Saitoh S, et al. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatol. 2006;44(6):1089-1097.
11. Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49(6):1954-1961.
12. Wen CP, Cheng TYD, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371(9631):2173-2182.
13. Wen CP, Wai JPM, Tsai MK, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet. 2011;378(9798):1244-1253.
14. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348-1355.
15. Department of Health. Statistics of causes of death. http://www.doh.gov. tw/EN2006/DM/DM2.aspx?now-fod-list-no=9256&class-no=390&level-no=2. Accessed July 26, 2012.
16. Grambsch PM, Therneau TM. Proportional hazards tests in diagnostics based on weighted residuals. Biometrika. 1994;81:551-526.
17. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-10.
18. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337-344.
19. D'Agostino RD, Nam BH. Evaluation of performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan N, Rao CR, eds. Handbook of Statistics. Vol 23. Amsterdam, the Netherlands: Elsevier; 2004:1-25.
20. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: John Wiley & Sons, Inc; 1999.
21. Sullivan LM, Massaro JM, D'Agostmo RB. Presentation of multivariate data for clinical use: the Framingham study risk score functions. Stat Med. 2004;23(10):1631-1660.
22. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer. 2000;85(4):498-502.
23. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4(3):369-380.